Malek Mushref, MD
Endocrinology, Diabetes & Metabolism · Athens, GANPI 1619339124
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 60.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $7,287 and has fallen 93.5% since, to $477 in 2025.
Across 117 payments — averaging $76.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$5K
- Medtronic$2K
- Abbott$358
- Novo Nordisk$273
- Lilly USA, LLC$273
- Insulet Corporation$223
- plus $780 from 15 others
What the payments were for
- Consulting fees$5,16058%
- Travel & lodging$1,08512%
- Food & beverage$2,60129%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 11 | $5,376 |
| Medtronic | 26 | $1,663 |
| Abbott | 8 | $358 |
| Novo Nordisk | 17 | $273 |
| Lilly USA, LLC | 12 | $273 |
| Insulet Corporation | 6 | $223 |
| Amgen | 8 | $148 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| AstraZeneca | 2 | $99 |
| Tandem Diabetes Care, Inc. | 3 | $67 |
| Bayer | 3 | $63 |
| Radius Health, Inc. | 2 | $54 |
| Corcept Therapeutics | 2 | $41 |
| Dexcom, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| AbbVie | 2 | $29 |
| Amphastar Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $23 |
| BETA Bionics, Inc. | 2 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$5,160
- MINIMED 780G$1,080
- FREESTYLE LIBRE 3$144
- Omnipod$129
How this compares
$8,946 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 199 | $357,298 |
| MounjaroTirzepatide | 146 | $282,073 |
| JardianceEmpagliflozin | 189 | $237,794 |
| TrulicityDulaglutide | 120 | $199,211 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $94,429 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 49 | $84,211 |
| TymlosAbaloparatide | 19 | $67,463 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $42,038 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $41,683 |
| JanuviaSitagliptin Phosphate | 45 | $40,280 |
| FarxigaDapagliflozin Propanediol | 33 | $39,722 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $38,842 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $30,027 |
| RybelsusSemaglutide | 13 | $26,031 |
| NovologInsulin Aspart | 44 | $22,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $273 | $493,781318 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $273 | $405,797256 claims |
| Boehringer IngelheimJardiance, Tradjenta | $35 | $252,814209 claims |
| Radius Health, Inc.Tymlos | $54 | $67,46319 claims |
| AstraZenecaFarxiga | $99 | $39,72233 claims |
| AbbVieSynthroid | $29 | $7,96769 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $5,063322 claims |
| Sanofi-aventis U.S. LLCLantus | $5,376 | $1,07112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Athens
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.